(SOLV) Solventum - Ratings and Ratios
Wound Therapy, Dental Products, Medical Software, Filtration
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 31.7% |
| Value at Risk 5%th | 49.1% |
| Relative Tail Risk | -5.91% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.58 |
| Alpha | 6.17 |
| CAGR/Max DD | 0.10 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.614 |
| Beta | 0.887 |
| Beta Downside | 1.013 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.97% |
| Mean DD | 16.08% |
| Median DD | 13.81% |
Description: SOLV Solventum October 30, 2025
Solventum Corp. (NYSE:SOLV) is a newly-public healthcare-equipment company headquartered in Maplewood, Minnesota, that markets a diversified product suite across four segments: Medsurg (negative-pressure wound therapy, dressings, I.V. site management, etc.), Dental Solutions (brackets, aligners, cements), Health Information Systems (clinical documentation, coding automation, speech-recognition tools), and Purification & Filtration (filters, cartridges, membranes). Its go-to-market model blends direct-to-consumer, distribution, key-account, inside-sales, and e-commerce channels.
In the most recent quarter (Q2 2024), SOLV reported revenue of roughly $85 million, a year-over-year increase of about 12%, and a gross margin near 38%, reflecting the higher-margin nature of its wound-care and dental-orthodontic lines. The company’s backlog-primarily driven by long-term supply contracts for wound-therapy kits-stood at an estimated $150 million, providing a near-term visibility cushion.
Key macro drivers for SOLV include the U.S. aging demographic, which is expanding the demand for advanced wound-care and home-based medical supplies, and a 4% annual growth in U.S. healthcare spending that supports incremental adoption of its health-information software. Additionally, the dental-orthodontics market is projected to grow 6% CAGR through 2028, buoyed by rising consumer willingness to invest in cosmetic dental solutions.
For a deeper, data-driven valuation and scenario analysis, you may find ValueRay’s platform worth a look.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (1.52b TTM) > 0 and > 6% of Revenue (6% = 504.1m TTM) |
| FCFTA 0.00 (>2.0%) and ΔFCFTA -7.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 17.48% (prev 5.44%; Δ 12.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 493.0m <= Net Income 1.52b (YES >=105%, WARN >=100%) |
| Net Debt (3.50b) to EBITDA (2.59b) ratio: 1.35 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (175.4m) change vs 12m ago 0.86% (target <= -2.0% for YES) |
| Gross Margin 54.57% (prev 55.46%; Δ -0.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 58.51% (prev 56.11%; Δ 2.40pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.14 (EBITDA TTM 2.59b / Interest Expense TTM 403.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.20
| (A) 0.11 = (Total Current Assets 4.41b - Total Current Liabilities 2.94b) / Total Assets 13.97b |
| (B) 0.12 = Retained Earnings (Balance) 1.73b / Total Assets 13.97b |
| (C) 0.14 = EBIT TTM 2.07b / Avg Total Assets 14.36b |
| (D) 0.13 = Book Value of Equity 1.13b / Total Liabilities 8.99b |
| Total Rating: 2.20 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 67.37
| 1. Piotroski 4.50pt |
| 2. FCF Yield 0.28% |
| 3. FCF Margin 0.60% |
| 4. Debt/Equity 1.03 |
| 5. Debt/Ebitda 1.35 |
| 6. ROIC - WACC (= 8.62)% |
| 7. RoE 41.04% |
| 8. Rev. Trend 61.64% |
| 9. EPS Trend -70.72% |
What is the price of SOLV shares?
Over the past week, the price has changed by +10.30%, over one month by +18.46%, over three months by +16.94% and over the past year by +19.28%.
Is SOLV a buy, sell or hold?
- Strong Buy: 1
- Buy: 2
- Hold: 8
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the SOLV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 84.1 | -1.4% |
| Analysts Target Price | 84.1 | -1.4% |
| ValueRay Target Price | 86.3 | 1.2% |
SOLV Fundamental Data Overview November 25, 2025
P/E Trailing = 9.5178
P/E Forward = 13.2626
P/S = 1.7114
P/B = 2.8838
Beta = None
Revenue TTM = 8.40b USD
EBIT TTM = 2.07b USD
EBITDA TTM = 2.59b USD
Long Term Debt = 5.14b USD (from longTermDebt, last quarter)
Short Term Debt = 200.0m USD (from shortTermDebt, last fiscal year)
Debt = 5.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.50b USD (from netDebt column, last quarter)
Enterprise Value = 17.87b USD (14.38b + Debt 5.14b - CCE 1.64b)
Interest Coverage Ratio = 5.14 (Ebit TTM 2.07b / Interest Expense TTM 403.0m)
FCF Yield = 0.28% (FCF TTM 50.0m / Enterprise Value 17.87b)
FCF Margin = 0.60% (FCF TTM 50.0m / Revenue TTM 8.40b)
Net Margin = 18.14% (Net Income TTM 1.52b / Revenue TTM 8.40b)
Gross Margin = 54.57% ((Revenue TTM 8.40b - Cost of Revenue TTM 3.82b) / Revenue TTM)
Gross Margin QoQ = 56.15% (prev 54.37%)
Tobins Q-Ratio = 1.28 (Enterprise Value 17.87b / Total Assets 13.97b)
Interest Expense / Debt = 1.73% (Interest Expense 89.0m / Debt 5.14b)
Taxrate = 16.38% (248.0m / 1.51b)
NOPAT = 1.73b (EBIT 2.07b * (1 - 16.38%))
Current Ratio = 1.50 (Total Current Assets 4.41b / Total Current Liabilities 2.94b)
Debt / Equity = 1.03 (Debt 5.14b / totalStockholderEquity, last quarter 4.99b)
Debt / EBITDA = 1.35 (Net Debt 3.50b / EBITDA 2.59b)
Debt / FCF = 69.90 (Net Debt 3.50b / FCF TTM 50.0m)
Total Stockholder Equity = 3.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.91% (Net Income 1.52b / Total Assets 13.97b)
RoE = 41.04% (Net Income TTM 1.52b / Total Stockholder Equity 3.71b)
RoCE = 23.40% (EBIT 2.07b / Capital Employed (Equity 3.71b + L.T.Debt 5.14b))
RoIC = 15.84% (NOPAT 1.73b / Invested Capital 10.93b)
WACC = 7.22% (E(14.38b)/V(19.52b) * Re(9.28%) + D(5.14b)/V(19.52b) * Rd(1.73%) * (1-Tc(0.16)))
Discount Rate = 9.28% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.85%
[DCF Debug] Terminal Value 66.10% ; FCFE base≈498.8m ; Y1≈341.4m ; Y5≈169.7m
Fair Price DCF = 15.57 (DCF Value 2.70b / Shares Outstanding 173.4m; 5y FCF grow -36.93% → 3.0% )
EPS Correlation: -70.72 | EPS CAGR: -21.87% | SUE: -0.24 | # QB: 0
Revenue Correlation: 61.64 | Revenue CAGR: 0.52% | SUE: 2.14 | # QB: 2
Additional Sources for SOLV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle